An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
Public ClinicalTrials.gov record NCT02320058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study of Nivolumab combined with Ipilimumab followed by Nivolumab by itself for the treatment of patients with Melanoma that has spread to the brain. Patients with histologically confirmed Malignant Melanoma and asymptomatic brain metastases are eligible for the study.
Study identification
- NCT ID
- NCT02320058
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 119 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 5, 2015 (Actual)
- Primary completion
- Sep 8, 2020 (Actual)
- Completion
- Sep 8, 2020 (Actual)
- Last update posted
- Oct 5, 2021
2015 – 2020
United States locations
- U.S. sites
- 36
- U.S. states
- 17
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | — |
| Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| UCLA Medical Hematology and Oncology | Los Angeles | California | 90095 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| The California Pacific Medical Research Institute | San Francisco | California | 94115 | — |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94158 | — |
| University of Colorado - Cancer Center - PPDS | Aurora | Colorado | 80045 | — |
| Washington Cancer Inst at MedStar Washington Hospital Ctr | Washington D.C. | District of Columbia | 20007 | — |
| Weinberg Cancer Institute At Franklin Square | Washington D.C. | District of Columbia | 20007 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20057 | — |
| Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| H Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| The Cleveland Clinic Foundation | Weston | Florida | 33331 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322-1013 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| Dana Farber Cancer Institute. | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02215 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| NYU Langone Medical Center | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Case School of Medicine University Hospitals of Cleveland | Cleveland | Ohio | 44106-5055 | — |
| Lehigh Valley Health Network | Allentown | Pennsylvania | 18105 | — |
| St Luke's Health Network | Easton | Pennsylvania | 18045 | — |
| Abramson Cancer Center of The University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Utah - Huntsman Cancer Institute - PPDS | Salt Lake City | Utah | 84112 | — |
| Inova Melanoma and Skin Cancer Center | Fairfax | Virginia | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02320058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 5, 2021 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02320058 live on ClinicalTrials.gov.